<p>Washed human platelets were loaded with fura2-AM and screened for drug-mediated inhibition of Ca<sup>2+</sup> release by 1 µg/ml CRP-XL (n = 3, ± SEM, representative traces and summary, a–c) and 1 µg/ml collagen (n = 3, SEM, representative traces and summary, d–f); losartan (▪) and cinanserin (▴). To measure aggregation, washed human platelets were incubated with drug for one minute prior to the addition of 1 μg/ml CRP-XL (representative traces and summary shown in g–i) or 1 µg/ml collagen (representative traces and summary shown in j–l).</p
Inappropriate platelet aggregation creates a cardiovascular risk that is largely managed with thieno...
Inappropriate platelet aggregation creates a cardiovascular risk that is largely managed with thieno...
Exposure of platelets to collagen triggers the formation of a platelet clot. Pharmacological agents ...
<p>Ca<sup>2+</sup> release and aggregations were carried out with 5 μM of the P<sub>2</sub>Y<sub>12<...
<p>Inhibition of collagen-induced Ca<sup>2+</sup> release (10 µg/ml) the sartans from fura2-AM-loade...
<p>Washed platelets in Mg<sup>2+</sup>- and Ca<sup>2+</sup>- free reaction buffer (A) or normal reac...
<p>Washed human platelets were assessed for effects on Ca<sup>2+</sup> release and aggregation (n = ...
<p>To assess effects on TPR signalling, platelets were activated with 1 µM U46619 and aggregations f...
<p>Washed platelets preincubated with PBS or losartan (22 μM), were stimulated with collagen (10 μg....
<p>Platelet aggregation responses to the GPVI-specific agonist CRP-XL were determined to a range of ...
<p>Washed platelets were preincubated with PBS or losartan (22 μM) for 10 min at 37°C. Buffer or TRA...
<div><p>Exposure of platelets to collagen triggers the formation of a platelet clot. Pharmacological...
Losartan and honokiol are small molecules which have been described to inhibit aggregation of platel...
<p>(A) Washed platelets pretreated with PBS or losartan (22 μM) were incubated with 5 μg.mL<sup>-1</...
Exposure of platelets to collagen triggers the formation of a platelet clot. Pharmacological agents ...
Inappropriate platelet aggregation creates a cardiovascular risk that is largely managed with thieno...
Inappropriate platelet aggregation creates a cardiovascular risk that is largely managed with thieno...
Exposure of platelets to collagen triggers the formation of a platelet clot. Pharmacological agents ...
<p>Ca<sup>2+</sup> release and aggregations were carried out with 5 μM of the P<sub>2</sub>Y<sub>12<...
<p>Inhibition of collagen-induced Ca<sup>2+</sup> release (10 µg/ml) the sartans from fura2-AM-loade...
<p>Washed platelets in Mg<sup>2+</sup>- and Ca<sup>2+</sup>- free reaction buffer (A) or normal reac...
<p>Washed human platelets were assessed for effects on Ca<sup>2+</sup> release and aggregation (n = ...
<p>To assess effects on TPR signalling, platelets were activated with 1 µM U46619 and aggregations f...
<p>Washed platelets preincubated with PBS or losartan (22 μM), were stimulated with collagen (10 μg....
<p>Platelet aggregation responses to the GPVI-specific agonist CRP-XL were determined to a range of ...
<p>Washed platelets were preincubated with PBS or losartan (22 μM) for 10 min at 37°C. Buffer or TRA...
<div><p>Exposure of platelets to collagen triggers the formation of a platelet clot. Pharmacological...
Losartan and honokiol are small molecules which have been described to inhibit aggregation of platel...
<p>(A) Washed platelets pretreated with PBS or losartan (22 μM) were incubated with 5 μg.mL<sup>-1</...
Exposure of platelets to collagen triggers the formation of a platelet clot. Pharmacological agents ...
Inappropriate platelet aggregation creates a cardiovascular risk that is largely managed with thieno...
Inappropriate platelet aggregation creates a cardiovascular risk that is largely managed with thieno...
Exposure of platelets to collagen triggers the formation of a platelet clot. Pharmacological agents ...